Royal Bank Of Canada Caladrius Biosciences, Inc. Transaction History

Royal Bank Of Canada

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.41 - $0.74 $395 - $714	965 Added 34.16%	3,790 $2,000
Q1 2022 May 16, 2022	BUY	$0.63 - $1.03 $22 - $36	35 Added 1.25%	2,825 $1,000
Q4 2021 Feb 14, 2022	BUY	$0.83 - $1.22 $1,660 - $2,440	2,000 Added 253.16%	2,790 $2,000
Q2 2021 Aug 16, 2021	BUY	$1.4 - $1.9 $1,106 - $1,501	790 New	790 $1,000

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.